Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer |
| |
| Affiliation: | 1. Department of Endocrinology, Monash Health, Monash Medical Centre, Clayton, Australia;2. Bone Joint and Cancer Unit, Prince Henry''s Institute, Block E, Level 4, Monash Medical Centre, Clayton, Australia;3. Department of Medicine, Southern Clinical School, Monash University, Clayton, Australia;4. Monash Cancer Centre, Centre Rd, Bentleigh, Australia;5. Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia;6. School of Public Health and Preventive Medicine, Monash University, Clayton, Australia;1. Institut Claudius Regaud, Toulouse, France;2. Quality of Life in Oncology Platform, Besançon, France;3. Methodological and Quality of Life Unit in Oncology, University Hospital of Besançon, Besançon, France;4. EA 3181, University of Franche-Comte, Besançon, France;5. Aix Marseille Université, Inserm, IRD, UMR_S912, SESSTIM, Marseille, France;6. APHMDepartment of Public Health, BiosTIC, Hôpital de la Timone, Marseille, France |
| |
| Abstract: | Prostate cancer is a leading cause of cancer death, frequently associated with widespread bone metastases. We report two cases of hypocalcemia following the first dose of denosumab in metastatic hormone refractory prostate cancer, the first case requiring 26 days of intravenous calcium therapy. This is the first report of prolonged hypocalcemia following denosumab in a patient with normal renal function. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
